Literature DB >> 30384975

The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.

Laleh S Arabanian1, Pegah Johansson2, Anna Staffas1, Tina Nilsson2, Arefeh Rouhi3, Linda Fogelstrand4, Lars Palmqvist5.   

Abstract

Endothelin receptor type A (EDNRA) is known as a mediator of cell proliferation and survival. Aberrant regulation of EDNRA has been shown to play a role in tumor growth and metastasis. Using a global gene expression screen, we found that expression of Ednra was upregulated in murine leukemia inducing cells co-expressing Hoxa9 and Meis1 compared to cells only expressing Hoxa9. The aim of this study was to explore the role of Ednra in leukemogenesis further. In a murine bone marrow transplantation model, mice transplanted with cells overexpressing Ednra and Hoxa9 succumbed to leukemia significantly earlier than mice transplanted with cells overexpressing Hoxa9 only. Furthermore, overexpression of Ednra led to increased proliferation and resistance to apoptosis of bone marrow cells in vitro. We could also show that Meis1 binds to the Ednra promoter region, suggesting a regulatory role for Meis1 in Ednra expression. Taken together, our results suggest a role for Ednra in Hoxa9/Meis1-driven leukemogenesis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Endothelin axis; Endothelin receptor type A; Hoxa9 and Meis1

Mesh:

Substances:

Year:  2018        PMID: 30384975     DOI: 10.1016/j.leukres.2018.10.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Myeloid ecotropic viral integration site-1 inhibition promotes apoptosis, suppresses proliferation of acute myeloid leukemia cells, accentuates the effects of anticancer drugs.

Authors:  Yinglan Jin; Jinghua Wang; Mingming Zhao; Jingyi Lin; Luojia Hong
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 2.  MEIS1 and its potential as a cancer therapeutic target (Review).

Authors:  Maozhong Yao; Yong Gu; Zhaoxin Yang; Keyan Zhong; Zhanjuan Chen
Journal:  Int J Mol Med       Date:  2021-07-28       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.